OXIPRO partner Barcelona Supercomputing Centre (BSC), together with its spinoff Nostrum Biodiscovery, are currently co-hosting an exhibition stand and presenting at BioJapan (October 11th-13th 2023), having recently returned from BioSpain, where they presented the OXIPRO project and its transformative developments.
BioSpain is the largest biotech event organized by a national bioindustry association in Europe and one of the largest in the world by the number of one-to-one meetings and companies participating. The XI BioSpain event, held from 26th to 29th September, gathered a record-breaking 2,100 attendees, and offered opportunities for collaboration among 975 companies from over 30 nations and more than 100 investors that came together at the sector meeting.
Meanwhile, BioJapan (October 11th-13th 2023) is Asia’s largest partnering event consisting of Exhibition, Seminar, and Partnering programmes. The event comprises three exhibitions: The world’s oldest biotechnology exhibition “BioJapan”; “Regenerative Medicine JAPAN” , which aims to accelerate and industrialize R&D in the field of regenerative medicine including iPS cells; and “health TECH JAPAN”, which provides a fusion of digital technology and life science.
The BSC team have been participating and exhibiting at both events, and discussing the ongoing efforts of different projects managed by its laboratory in partnership with Nostrum Biodiscovery, a spin-off from BSC that commercialises molecular modelling and machine learning technology for the discovery and design of active molecules and biomolecules. BSC had the opportunity to explain and present the progress of OXIPRO to the attendees and different biotechnological companies interested in the innovative enzymatic systems under development. Specifically, discussions were held with companies such as Darwin Bioprospecting, Lucas Biotech, CLaMber, and Mediterranean Algae – all of whom were interested in BSC’s enzymatic engineering efforts.
“Taking part in BioSpain and BioJapan has been a great opportunity to catch up with the current trends in the biotechnological companies worldwide, and especially in the global markets. Indeed, biocatalysis does not have a majority presence in the ongoing biotech industry. Still, we hope this will change in the years to come with the advance of more powerful methodologies. Nonetheless, we expect the discussion we held can lead us to open new avenues for the future commercialisation of our developing products”, says Martin Floor, a key member of the BSC research team led by Victor Guallar.